Introduction {#s1}
============

In December 2019, a new type of β-coronavirus named the 2019 novel coronavirus (SARS-CoV-2) emerged in Wuhan, China, and spread rapidly throughout the world ([@B1]). As of May 31, 2020, 5.9 million cases of coronavirus disease 2019 (COVID-19) have been confirmed, including 367 thousand deaths ([@B2]). It was most likely initially a zoonotic infectious disease, but effective transmission between people was soon discovered ([@B3]). The clinical symptoms of SARS-CoV-2 infection are variable, including being asymptomatic, upper respiratory tract disease, viral pneumonia, fatigue, gastrointestinal symptoms, respiratory failure, and even death ([@B4], [@B5]). Its clinical characteristics have been well-evaluated, but effective predictors for clinical outcome and research on the underlying mechanisms are scarce ([@B6]). Identification of effective predictors could help to judge the prognosis and optimal intervention measures for COVID-19 patients at an early stage.

Therefore, 95 hospitalized COVID-19 pneumonia patients with definitive clinical outcome (cured or died) were retrospectively selected between February 5, 2020, and March 11, 2020. The clinical characteristics of the 95 hospitalized patients are described. Moreover, factors predicting the prognosis of patients with COVID-19 pneumonia were investigated in this study.

Materials and Methods {#s2}
=====================

Study Design and Participants
-----------------------------

This retrospective case-control study enrolled a total of 95 cases admitted to Tongji hospital between February 5, 2020, and March 8, 2020, with confirmed COVID-19 pneumonia. In brief, the patients were all hospitalized probable subjects in four wards of Tongji hospital with (1) positive throat swab nucleic acid test by real-time RT-PCR methods or positive for SARS-CoV-2-specific antibodies, (2) chest radiographic evidence of pneumonia, (3) rehabilitation discharge or died in hospital between February 20, 2020, and March 11, 2020. Patients who were discharged from hospital in 24 h or died within 24 h after hospitalization were excluded from this study. This study was reviewed and approved by the ethics committee of Tongji Hospital, Huazhong University of Science and Technology (IRB ID:TJ- IRB20200343).

Data Collection
---------------

Clinical, laboratory, and radiological results were collected from electronic medical records. Data were obtained with standardized forms for all subjects involved. Two researchers independently collected and reviewed the data.

Outcomes
--------

Two outcomes were evaluated: "cured" or "died." The criteria for rehabilitation discharge or being cured were (1) no fever for at least 3 days; (2) substantial improvement in chest CT scan or X-ray images; (3) negative nucleic acid test two consecutive times with at least a 24-h interval between them.

Statistical Analysis
--------------------

Descriptive analyses of the continuous variables were expressed as mean or median with interquartile range (IQR). Categorical variables were described as frequency rates and percentages. Differences in continuous variables were analyzed using *t*-tests when normally distributed or otherwise with the Mann-Whitney test. Categorical variables were compared using the χ^2^ test. The ROC curve was used to analyze the predictive factors, and the area under the ROC curve (AUC) was calculated. Correlation analysis was evaluated by the Pearson test. The appropriate sample size for inferences was determined based on the Wilcoxon statistics, where the statistical power was 0.8 (1--β) and α = 0.05. Forward stepwise, binary logistic regression was performed on the covariates. All tests were two-sided, and *P* \< 0.05 was considered statistically significant. The statistical software SPSS 23.0 was used in this study.

Results {#s3}
=======

The Characterization of Patients
--------------------------------

A total of 95 COVID-19 patients (58 men and 37 women) were included in the study ([Table 1](#T1){ref-type="table"}). The median age was 65 years old. As of March 11, 56 patients (58.9%) had been discharged, and 39 (41.1%) had died. The all-cause mortality rate in these COVID-19 patients was 22.4%. Of the 95 patients, 68 (71.6%) had one or more pre-existing diseases. Hypertension (40 \[42.1%\]), diabetes (22 \[23.2.1%\]), cardiovascular disease (10 \[10.5%\]), and malignancies (6 \[6.3%\]) were the most common. The chief complaints were fever (71 \[74.7%\]), cough (13 \[13.7%\]), dyspnea (6 \[6.3%\]), and other uncommon symptoms. Of the 95 patients, bilateral involvement was detected in chest CT or X-ray images of 92 (97%) patients. The mean hospitalization duration was 21 (14.0--25.0) days. People who died were significantly older (70 years \[IQR 60--77\] vs. 62 years \[IQR 50.5--72\]; *p* = 0.008), more likely to have malignancies (5 \[13%\] vs. 1 \[2%\]; *p* = 0.030), while other variables (i.e., gender, hypertension, diabetes, cardiovascular disease, COPD, hospital stay) were similar between the two groups.

###### 

Baseline characteristics of patients included in the study.

  ------------------------------------------------------------------------------------------
                          **Total**\       **Cured**\       **Died**\        ***P*-value**
                          **(*n* = 95)**   **(*n* = 56)**   **(*n* = 39)**   
  ----------------------- ---------------- ---------------- ---------------- ---------------
  Age, years              65 (56--76)      62 (50.5--72)    70 (60--77)      0.008

  Sex                                                                        0.073

      Male                58 (61%)         30 (54%)         28 (72%)         

      Female              37 (39%)         26 (46%)         11 (28%)         

  Any comorbidities       68 (72%)         37 (66%)         31 (79%)         0.154

      Hypertension        40 (42%)         23 (41%)         17 (44%)         0.807

      Diabetes            22 (23%)         12 (21%)         10 (26%)         0.632

      Cardiovascular      10 (12%)         5 (9%)           5 (13%)          0.543

      disease                                                                

      COPD                6 (6%)           3 (5%)           3 (8%)           0.645

      Malignancy          6 (6%)           1 (2%)           5 (13%)          0.030

      Chronic renal       7 (7%)           6 (11%)          1 (3%)           0.135

      disease                                                                

      Others              15 (16%)         7 (13%)          8 (21%)          0.292

  Chief complaint                                                            

      Fever               71 (75%)         42 (75%)         29 (74%)         0.944

      Cough               11 (16%)         7 (13%)          6 (15%)          0.687

      Dyspnea             6 (6%)           4 (7%)           2 (5%)           0.691

      Others              5 (5%)           3 (5%)           2 (5%)           0.961

  Bilateral involvement                                                      0.142

      Yes                 92 (97%)         53 (95%)         39 (100%)        

      No                  3 (3%)           3 (5%)           0 (0%)           

  Hospital stay, days     21.0\            21.1\            18.4\            0.057
                          (14.0--25.0)     (15.0--27.0)     (13.0--22.0)     
  ------------------------------------------------------------------------------------------

Laboratory Parameters in the Cured and Died Groups
--------------------------------------------------

The blood count of patients on admission showed a decrease in lymphocytes, especially in the died group ([Table 2](#T2){ref-type="table"}). Consistent with this, most lymphocyte subsets (T cells, Th cells, Ts cells, and NK cells) detected by flow cytometry were significantly higher in survivors than in non-survivors. Meanwhile, leucocyte count and neutrophil count were higher in deceased patients (leucocyte 9.9 × 10^9^ per L \[7.3--12.6\]; neutrophil 8.6 × 10^9^ per L \[6.1--11.4\]) than in cured patients (leucocyte 8.6 × 10^9^ per L \[6.1--11.4\], *p* \< 0.001; neutrophil 4.6 × 10^9^ per L \[3.1--5.2\], *p* = 0.001). Prothrombin time and D-dimer levels were higher in deceased patients (PT 16.1 s \[14.3--15.8\]; D-dimer 5.8 mg/L \[1.4--6.8\]) than in cured patients (PT 13.9 s \[13.2--14.5\], *p* \< 0.001; D-dimer 2.8 mg/L \[0.4--2.0\], *p* = 0·001). Blood urea nitrogen levels, C-reactive protein (CRP) levels and Procalcitonin levels were higher in deceased patients (BUN 9.9 mmol/L \[5.9--10.5\]; CRP 123.2 mg/L \[38.3--213.2\]; Procalcitonin 1.3 ng/mL \[0.1--0.6\]) than in cured patients (BUN 5.9 mmol/L \[3.7--6.4\]), *p* \< 0.001; CRP 43.5 mg/L \[2.4--63.9\], *p* = 0.006; Procalcitonin 0.2 ng/mL \[0--0.1\], *p* \< 0.001). Serum albumin levels were lower in deceased patients (albumin 30.5 g/L \[27.6--33.5\]) than in cured patients (albumin 35.2 g/L \[32.0--37.8\], *p* = 0.022), while serum total bilirubin and lactate dehydrogenase levels were higher in deceased patients (T-Bil 13.3 μmol/L \[9.8--17.6\]; LDH 503.0 U/L \[304.0--659.0\]) than in cured patients (T-Bil 10.0 μmol/L \[6.3--13.5\], *p* = 0.010; LDH 305.4 U/L \[212.5--348.3\], *p* \< 0.001), indicating hepatic dysfunction in more patients in the died group. The levels of most cytokines (IL2R, IL6, IL8, IL10, and TNF-α) were significantly higher in non-survivors than in survivors. No significant differences in serum creatine and BNP levels existed between deceased patients and cured patients (*p* \> 0.05). As determined based on the Wilcoxon statistics ([@B7]), the sample size needed for evaluating CRP, Procalcitonin, LDH, IL6, neutrophil percentage, lymphocyte percentage, and T cells were 31 patients (18 cases cured, 13 cases died), 244 patients (144 cases cured, 100 cases died), 41 patients (24 cases cured, 17 cases died), 56 patients (33 cases cured, 23 cases died), 29 patients (17 cases cured, 12 cases died), 27 patients (16 cases cured, 11 cases died), and 103 patients (61 cases cured, 42 cases died), respectively.

###### 

Laboratory findings of patients with COVID-19.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                    **Total**\                                        **Cured**\                                        **Died**\                                         ***P*-value**
                                    **(*n* = 95[^\*^](#TN1){ref-type="table-fn"})**   **(*n* = 56[^\*^](#TN1){ref-type="table-fn"})**   **(*n* = 39[^\*^](#TN1){ref-type="table-fn"})**   
  --------------------------------- ------------------------------------------------- ------------------------------------------------- ------------------------------------------------- ---------------
  Hemoglobin,\                      126.0\                                            122.3\                                            131.5\                                            0.009
  g per L                           (116.0--138.0)                                    (115.3--128.8)                                    (117.0--149.0)                                    

  Alanine aminotransferase, U/L     38.9\                                             32.4\                                             48.2\                                             0.142
                                    (15.0--44.0)                                      (14.0--43.3)                                      (18.0--46.0)                                      

  Aspartate aminotransferase, U/L   42.5\                                             33.8\                                             54.9\                                             0.022
                                    (21.0--45.0)                                      (19.3--41.3)                                      (24.0--56.0)                                      

  Albumin, g/L                      33.3\                                             35.2\                                             30.5\                                             \<0.001
                                    (29.7--33.9)                                      (32.0--37.8)                                      (27.6--33.5)                                      

  Total bilirubin, umol/L           11.4\                                             10.0\                                             13.3\                                             0.010
                                    (7.0--14.2)                                       (6.3--13.5)                                       (9.8--17.6)                                       

  Lactate dehydrogenase, U/L        386.6\                                            305.4\                                            503.0\                                            \<0.001
                                    (227.0--479.0)                                    (212.5--348.3)                                    (304.0--659.0)                                    

  Blood urea nitrogen, mmol/L       7.6\                                              5.9\                                              9.9\                                              0.002
                                    (4.1--8.6)                                        (3.7--6.4)                                        (5.9--10.5)                                       

  Creatinine, umol/L                119.4\                                            115.7\                                            124.7\                                            0.796
                                    (59.0--98.0)                                      (56.0--92.8)                                      (65.0--120.0)                                     

  Prothrombin time, second          14.8\                                             13.9\                                             16.1\                                             \<0.001
                                    (13.5--15.1)                                      (13.2--14.5)                                      (14.3--15.8)                                      

  D--dimer, ug/mL                   4.0\                                              2.8\                                              5.8\                                              0.001
                                    (0.6--4.4)                                        (0.4--2.0)                                        (1.3--6.8)                                        

  Platelets, × 10^9^ per L          219.1\                                            232.1\                                            200.4\                                            0.137
                                    (147.0--291.0)                                    (171.8--304.5)                                    (121.0--255.0)                                    

  Procalcitonin, ng/mL              0.7\                                              0.2\                                              1.3\                                              \<0.001
                                    (0.0--0.4)                                        (0--0.1)                                          (0.1--0.6)                                        

  C--reactive protein, mg/L         69.4\                                             43.5\                                             123.2\                                            0.006
                                    (3.4--105.4)                                      (2.4--63.9)                                       (38.3--213.2)                                     

  BNP, pg/mL                        1739.1\                                           1653.4\                                           1848.0\                                           0.859
                                    (95.5--1274.8)                                    (67.0--457.0)                                     (413.5--1472.0)                                   

  IL2R, U/mL                        998.4\                                            851.5\                                            1188.9\                                           0.010
                                    (499.5--1390.1)                                   (413.0--1250.0)                                   (861.0--1522.0)                                   

  IL6, pg/mL                        79.3\                                             31.9\                                             139.1\                                            \<0.001
                                    (4.4--65.7)                                       (2.6--38.5)                                       (21.3--146.8)                                     

  IL8, pg/mL                        28.6\                                             18.5\                                             41.7\                                             \<0.001
                                    (8.6--33.9)                                       (7.1--22.7)                                       (16.5--48.9)                                      

  IL10, pg/mL                       5.7\                                              3.2\                                              8.8\                                              0.036
                                    (0--8.4)                                          (0--5.4)                                          (0--10.1)                                         

  TNF--α, pg/mL                     10.9\                                             9.3\                                              13.1\                                             0.009
                                    (6.9--13.7)                                       (5.7--12.2)                                       (8.3--15.6)                                       

  Leucocytes, × 10^9^ per L         7.9\                                              6.5\                                              9.9\                                              \<0.001
                                    (5.1--9.0)                                        (4.6--7.5)                                        (7.3--12.6)                                       

  Neutrophils, × 10^9^ per L        6.3\                                              4.6\                                              8.6\                                              \<0.001
                                    (3.5--7.6)                                        (3.1--5.2)                                        (6.1--11.4)                                       

  Neutrophil percentage, %          76.1\                                             69.2\                                             85.9\                                             \<0.001
                                    (66.8--87.1)                                      (61.2--75.0)                                      (80.8--91.6)                                      

  Lymphocytes, × 10^9^ per L        1.0\                                              1.2\                                              0.7\                                              \<0.001
                                    (0.6--1.4)                                        (0.7--1.6)                                        (0.3--0.7)                                        

  Lymphocyte percentage, %          15.3\                                             20.5\                                             7.9\                                              \<0.001
                                    (6.9--22.6)                                       (14.9--27.0)                                      (4.6--9.9)                                        

  Monocytes, × 10^9^ per L          0.5\                                              0.5\                                              0.5\                                              0.850
                                    (0.3--0.6)                                        (0.4--0.6)                                        (0.3--0.7)                                        

  Eosinophils, × 10^9^ per L        0.1\                                              0.1\                                              0\                                                0.056
                                    (0--0.1)                                          (0--0.1)                                          (0--0)                                            

  Basophils, × 10^9^ per L          0\                                                0\                                                0\                                                0.184
                                    (0--0)                                            (0--0)                                            (0--0)                                            

  T cells\                          556.9\                                            1073.3\                                           322.2\                                            \<0.001
  (CD3+CD19--) /ul                  (206.3--880.3)                                    (842.0--1499.3)                                   (125.0--471.3)                                    

  T cells\                          14.3\                                             74.9\                                             64.0\                                             0.042
  (CD3+CD19--) %                    (56.1--78.8)                                      (68.3--80.4)                                      (54.4--75.0)                                      

  B cells\                          115.4\                                            114.1\                                            116.0\                                            0.958
  (CD3--CD19+) /ul                  (41.5--150.3)                                     (49.8--167.5)                                     (36.8--146.8)                                     

  B cells\                          19.2\                                             8.9\                                              23.9\                                             0.005
  (CD3--CD19+) %                    (9.4--29.6)                                       (4.1--11.4)                                       (10.5--33.4)                                      

  Th cells\                         369.8\                                            707.5\                                            216.4\                                            \<0.001
  (CD3+CD4+) /ul                    (107.3--587.0)                                    (505.0--924.5)                                    (85.3--239.3)                                     

  Th cells\                         44.3\                                             49.4\                                             42.0\                                             0.189
  (CD3+CD4+) %                      (31.7--57.3)                                      (43.1--58.7)                                      (30.4--57.5)                                      

  Ts cells\                         168.5\                                            327.6\                                            96.2\                                             \<0.001
  (CD3+CD8+) /ul                    (53.3--265.0)                                     (256.3--365.8)                                    (32.5--131.5)                                     

  Ts cells\                         21.1\                                             22.7\                                             20.4\                                             0.661
  (CD3+CD8+) %                      (12.2--23.1)                                      (17.2--27.9)                                      (11.3--21.3)                                      

  NK cells\                         104.1\                                            223.3\                                            49.9\                                             \<0.001
  (CD3--/CD16+\                     (26.5--121.0)                                     (99.8--293.5)                                     (15.0--69.8)                                      
  CD56+) /ul                                                                                                                                                                              

  NK cells\                         12.3\                                             14.8\                                             11.1\                                             0.326
  (CD3--/CD16+\                     (6.3--16.0)                                       (6.7--17.0)                                       (4.9--16.2)                                       
  CD56+) %                                                                                                                                                                                

  T cells+B cells+NK cells /ul      776.5\                                            1410.7\                                           488.2\                                            \<0.001
                                    (98.6--1146.5)                                    (1118.3--1902.5)                                  (262.8--713.3)                                    

  T cells+B cells+NK cells %        98.9\                                             98.7\                                             99.0\                                             0.329
                                    (98.6--99.5)                                      (98.1--99.5)                                      (98.7--99.5)                                      

  Th/Ts                             2.9\                                              2.4\                                              3.1\                                              0.304
                                    (1.6--3.9)                                        (1.7--2.9)                                        (1.5--4.5)                                        
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*C-reactive protein levels were tested in 46 patients (31 cases cured, 15 cases died), cytokine levels were tested in 85 patients (48 cases cured, 37 cases died), while lymphocyte subgroups were tested in 32 patients (10 cured, 22 died)*.

*INR, International standardized ratio; Th cells, helper T cells; Ts cells, suppressor T cells; NK cells, natural killer cells. Continuous variables are described as mean (IQR)*.

Prognostic Factors of Patients With COVID-19 Pneumonia
------------------------------------------------------

ROC curve analysis was performed to evaluate the prognostic factors for COVID-19. The neutrophil-to-lymphocyte ratio (NLR) is a well-known marker of systemic inflammation ([@B8]). Therefore, we evaluated the efficiency of NLR and other potential predictors (neutrophil to T lymphocyte count ratio, NTR; neutrophil percentage to T lymphocyte ratio, NpTR) in predicting mortality. As shown in [Table 3](#T3){ref-type="table"} and [Figures 1A--C](#F1){ref-type="fig"}, factors associated with peripheral blood cell count (neutrophils, neutrophil percentage, lymphocyte percentage, T cells, B cells, Th cells, Ts cells, NK cells, T cells+B cells+NK cells, NLR, NTR, and NpTR) and inflammation-associated factors (Procalcitonin, IL6) showed good prognostic values, among which NpTR was the most predominant predictive factor for the clinical outcome (0.932; 95% CI: 0.810--1.000, *p* \< 0.001; [Figure 1C](#F1){ref-type="fig"}). Furthermore, binary logistic regression models showed that NpTR was the independent prognostic factor for death (OR =59993.937, 95% CI: 4.130--871565732.1; *p* = 0.024; [Table 4](#T4){ref-type="table"}). The Nagelkerke R value was 0.811. The condition indexes for age, LDH, and NpTR were 2.6, 5.4, and 18.6, respectively. To minimize potential confounding effects of age, a matched case-control study was performed (each deceased patient was matched with one cured patient with an age difference of 4 years or less). Both the matched and unmatched analyses yielded similar results ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}).

###### 

Prognostic value of the clinical parameters.

                                **Number**   **ACU**   **95% Confidence interval**   ***P*-value**
  ----------------------------- ------------ --------- ----------------------------- ---------------
  Age                           95           0.658     0.549--0.768                  0.009
  Malignancy                    95           0.555     0.435--0.675                  0.362
  Hemoglobin, g per L           95           0.657     0.537--0.777                  0.009
  Aspartate aminotransferase    95           0.638     0.525--0.751                  0.022
  Albumin                       95           0.739     0.637--0.840                  \<0.001
  Total bilirubin               95           0.695     0.591--0.800                  0.001
  Lactate dehydrogenase         95           0.784     0.689--0.879                  \<0.001
  Blood urea nitrogen           95           0.782     0.687--0.877                  \<0.001
  Prothrombin time              95           0.772     0.671--0.873                  \<0.001
  D--dimer                      95           0.708     0.598--0.819                  0.001
  Procalcitonin                 95           0.822     0.734--0.910                  \<0.001
  C--reactive protein           46           0.759     0.610--0.907                  0.007
  IL2R                          85           0.684     0.570--0.798                  0.004
  IL6                           85           0.811     0.721--0.901                  \<0.001
  IL8                           85           0.738     0.631--0.845                  \<0.001
  IL10                          85           0.720     0.606--0.835                  0.001
  TNFa                          85           0.678     0.562--0.793                  0.005
  Leucocytes                    95           0.798     0.702--0.895                  \<0.001
  Neutrophils                   95           0.851     0.766--0.937                  \<0.001
  Neutrophil percentage         95           0.900     0.837--0.964                  \<0.001
  Lymphocytes                   95           0.777     0.683--0.870                  \<0.001
  Lymphocyte percentage         95           0.897     0.833--0.962                  \<0.001
  Monocyte                      95           0.521     0.395--0.647                  0.728
  Eosinophils                   95           0.755     0.655--0.855                  \<0.001
  Basophils                     95           0.554     0.437--0.670                  0.376
  T cells (CD3+CD19--)          32           0.925     0.808--1.000                  \<0.001
  T cells (CD3+CD19--)%         32           0.732     0.543--0.920                  0.038
  B cells (CD3--CD19+)%         32           0.805     0.653--0.956                  \<0.001
  Th cells (CD3+CD4+)           32           0.900     0.771--1.000                  \<0.001
  Ts cells (CD3+CD8+)           32           0.902     0.776--1.000                  \<0.001
  NK cells (CD3--/CD16+CD56+)   32           0.877     0.731--1.000                  0.001
  T cells+B cells+NK cells      32           0.918     0.780--1.000                  \<0.001
  NLR                           32           0.900     0.837--0.964                  \<0.001
  NTR                           32           0.905     0.727--1.000                  \<0.001
  NpTR                          32           0.932     0.810--1.000                  \<0.001

*NLR, neutrophil-to-lymphocyte ratio; NTR, neutrophil to T lymphocyte count ratio; NpTR, neutrophil percentage to T lymphocyte ratio; Th cells, helper T cells; Ts cells, suppressor T cells; NK cells, natural killer cells*.

![Efficiency of cytokine and leucocyte subsets in predicting the clinical outcome of patients with COVID-19 pneumonia. **(A--C)** Efficiency of serum cytokine and leucocyte subsets in predicting the mortality of patients. **(D--G)** Serum IL6 levels were positively correlated with lymphocyte count, neutrophil count, and eosinophil count and negatively correlated with lymphocyte count.](fpubh-08-00299-g0001){#F1}

###### 

Logistic regression of independent prognostic factors for mortality.

  **Factors**   **β**    **S$\overline{x}$**   ***P*-value**   **OR for Mortality (95% CI)**
  ------------- -------- --------------------- --------------- --------------------------------
  Age           0.134    0.108                 0.214           1.143 (0.925--1.412)
  PT            2.334    1.258                 0.064           10.323 (0.877--121.5630.690)
  NpTR          11.002   4.890                 0.024           59993.937 (4.130--871565732.1)

*NpTR, neutrophil percentage to T lymphocyte ratio; PT, Prothrombin time*.

Correlations Between Leucocyte Subsets and Inflammation-Related Factors
-----------------------------------------------------------------------

We subsequently explored the correlations between leucocyte subsets and inflammation-related factors (IL2R, IL6, IL8, TNF-α, CRP, and Procalcitonin) associated with clinical outcome. Interestingly, serum IL6 levels were positively correlated with leucocyte count, neutrophil count, and eosinophil count (*r* = 0.286, *p* = 0.008; *r* = 0.298, *p* = 0.005; *r* = 0.281, *p* = 0.009, resp.) and negatively correlated with lymphocyte count (*r* = −0.226, *p* = 0.037) but not monocyte count, as shown in [Table 5](#T5){ref-type="table"} and [Figures 1D--G](#F1){ref-type="fig"}. Meanwhile, leucocytes, neutrophils, and eosinophils were positively correlated with most inflammatory factors (IL2R, IL6, IL8, TNF-α, CRP, and Procalcitonin), as shown in [Table 5](#T5){ref-type="table"}. No significant correlations were found between lymphocyte subsets and inflammatory factors (IL2R, IL6, IL8, TNF-α, and Procalcitonin) (*p* \> 0.05).

###### 

Correlation analysis was evaluated between leucocyte subsets and inflammatory factors.

                   **IL2R**                                  **IL6**                                    **IL8**                                    **IL10**                                   **TNF-α**                                  **CRP**                                     **PCT**
  ---------------- ----------------------------------------- ------------------------------------------ ------------------------------------------ ------------------------------------------ ------------------------------------------ ------------------------------------------- ------------------------------------------
  Leucocytes       0.232[^\*^](#TN2){ref-type="table-fn"}    0.286[^\*\*^](#TN3){ref-type="table-fn"}   0.382[^\*\*^](#TN3){ref-type="table-fn"}   0.474[^\*\*^](#TN3){ref-type="table-fn"}   0.126                                      0.440[^\*\*^](#TN3){ref-type="table-fn"}    0.196
  Neutrophils      0.247[^\*^](#TN1){ref-type="table-fn"}    0.298[^\*\*^](#TN3){ref-type="table-fn"}   0.403[^\*\*^](#TN3){ref-type="table-fn"}   0.474[^\*\*^](#TN3){ref-type="table-fn"}   0.123                                      0.500[^\*\*^](#TN3){ref-type="table-fn"}    0.177
  Lymphocytes      −0.218[^\*^](#TN1){ref-type="table-fn"}   −0.225[^\*^](#TN1){ref-type="table-fn"}    −0.226[^\*^](#TN1){ref-type="table-fn"}    −0.185                                     −0.147                                     −0.422[^\*\*^](#TN3){ref-type="table-fn"}   −0.025
  Monocyte         0.084                                     0.120                                      −0.007                                     0.111                                      0.107                                      0.159                                       −0.004
  Eosinophils      0.203[^\*^](#TN1){ref-type="table-fn"}    0.281[^\*\*^](#TN3){ref-type="table-fn"}   0.234[^\*^](#TN1){ref-type="table-fn"}     0.463[^\*\*^](#TN3){ref-type="table-fn"}   0.390[^\*\*^](#TN3){ref-type="table-fn"}   −0.348[^\*^](#TN1){ref-type="table-fn"}     0.667[^\*\*^](#TN3){ref-type="table-fn"}
  T cells          −0.165                                    0.035                                      −0.021                                     0.010                                      −0.188                                     −0.316                                      0.138
  B cells          0.091                                     0.093                                      0.068                                      0.053                                      −0.048                                     0.486[^\*^](#TN1){ref-type="table-fn"}      0.028
  Th cells         −0.085                                    0.123                                      0.025                                      0.075                                      −0.173                                     −0.236                                      0.202
  Ts cells         −0.279                                    −0.136                                     −0.103                                     −0.127                                     −0.176                                     −0.374                                      −0.020
  NK cells         −0.321                                    −0.231                                     −0.208                                     −0.195                                     −0.119                                     −0.531[^\*^](#TN1){ref-type="table-fn"}     −0.088
  T +B +NK cells   −0.199                                    −0.014                                     −0.057                                     −0.031                                     −0.190                                     −0.325                                      0.094

*Data expressed as correlation coefficient*.

P \< 0.05;

*P \< 0.01. NK cells, natural killer cells; Th cells, helper T cells; Ts cells, suppressor T cells; CRP, C-reactive protein; PCT, Procalcitonin*.

Discussion {#s4}
==========

We retrospectively analyzed the clinical characteristics and laboratory parameters in 95 COVID-19 patients with definitive clinical outcome and found that leucocyte subsets and inflammatory factors showed good prognostic values and that non-self-limiting inflammatory response may be involved in the development of fatal pneumonia induced by SARS-CoV-2 infection.

As previously reported, older age, a coagulation disorder, bacterial infection, malfunctions in the liver, heart, or kidney, and changes in blood cell count are associated with the prognosis of COVID-19 patients ([@B4], [@B6]). Similarly, we found that older age, lower albumin, and higher serum LDH levels, BUN levels, and PT indicated poor outcome. Patients with increased levels of organ damage-associated biomarkers were more likely to develop complications such as fetal acute lung injury (ALI) and multiple organ dysfunction syndrome. Moreover, the leucocyte count or neutrophil count was higher in the died group and predicted the mortality in COVID-19 patients, verified by ROC curves, while lymphocyte subset (lymphocytes, T cells, Th cells, Ts cells, NK cells, T cells+B cells+NK cells) counts were positively associated with cure rate, among which the AUC for T cells was the highest (AUC: 0.925, *P* \< 0.001). NLR is a well-known marker of systemic inflammation ([@B8]), so we evaluated NLR and other potential predictors (NTR, NpTR) originating from the existing parameters. ROC curves showed that NLR, NTR, and NpTR could effectively predict the mortality in patients with COVID-19 pneumonia (AUC: 0.900, *P* \< 0.001; AUC: 0.905, *P* \< 0.001; AUC: 0.932, *P* \< 0.001, resp.).

Despite a series of studies, specific factors causing the high mortality of COVID-19 are incompletely understood. Respiratory failure is the main cause of mortality in COVID-19 patients ([@B4], [@B9]). Severe pneumonia caused by pathogenic human coronavirus is often associated with high viral load, massive inflammatory cell infiltration, and elevated cytokine responses resulting in ALI ([@B10], [@B11]). Consistent with the above findings, histological examination of lungs from patients dead from COVID-19 revealed extensive leucocyte infiltration, overactivated T lymphocytes being the predominant cell type ([@B9]). Hyper-inflammatory cytokines can amplify inflammatory responses by promoting unrestrained virus replication ([@B12]). Furthermore, coronavirus-infected patients may die of ALI despite successful viral elimination ([@B13]). Consistent with previous studies ([@B4], [@B14]), we found that higher levels of inflammation-associated factors (IL2R, IL6, IL8, TNF-α, CRP, and Procalcitonin) indicated poor outcome, indicating that powerful positive feedback between virus infection and hyperinflammation might be critical in lung destruction and disease morbidity. IL6 was a powerful predictor of mortality and closely correlated with leucocyte, neutrophil, lymphocyte, and eosinophil counts. Thus, IL6 receptor blockade (tocilizumab), which has been approved for a clinical COVID-19 treatment trial in China (ChiCTR2000029765), is a new and promising treatment for COVID-19. IL-10 was highly expressed in non-survivors, indicating the failure to limit and ultimately terminate hyperinflammation in severe patients ([@B15]). Meanwhile, lymphocytes play an important role in SARS-CoV-2 elimination, as indicated by the production of larger amounts of granzymes and perforin in a mild-moderate patient ([@B16]). There was no significant elevation of cytokines in this mild-moderate patient, further indicating the key role of cytokines in disease progression. Middle East respiratory syndrome coronavirus (MERS) can efficiently infect human T cells and induced apoptosis in human T lymphocytes ([@B17]), so it is speculated that both redistribution to the target organ and depletion contribute to lymphocyte decline, both of which indicate poor outcome. Studies have demonstrated that T-cell responses can inhibit the overactivation of innate immunity ([@B18]). As described in our study, leucocytes, neutrophils, and eosinophils were positively correlated with most inflammatory factors (IL2R, IL6, IL8, TNF-α, CRP, and Procalcitonin), indicating that neutrophils and eosinophils might contribute to cytokine release. Meanwhile, lymphocyte count significantly decreased in fatal cases and was negatively correlated with IL6 levels, indicating negative feedback between lymphocytes and IL6 during coronavirus infection. Dysfunction of lymphocytes in both virus clearance and inhibition of cytokine overactivation may contribute to excessive inflammatory response. Thus, non-self-limiting inflammatory response and lymphocyte dysfunction may be the key mechanisms in fatal pneumonia induced by SARS-CoV-2 infection. Probably because of the limited number of cases detected, no correlations were found between lymphocyte subsets and inflammatory factors.

This study does have some limitations. Firstly, owing to the retrospective nature of this study, results for viral load not available. Secondly, it is a single-center study with a limited number of cases. In addition, the majority of patients admitted to our hospital were critically ill, so population bias exists, though a confounding effect of age has been ruled out.

Conclusion {#s5}
==========

In summary, our results demonstrate that leucocyte subsets and inflammation-related factors predict the clinical outcome of patients with COVID-19 pneumonia with high efficiency, among which T cells and NpTR are most predominant. Non-self-limiting inflammatory response and lymphocyte dysfunction may be the key mechanisms in fatal pneumonia induced by SARS-CoV-2 infection. This provides evidence for laboratory diagnostics and clinical interventions.
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